Medication info
Pelore 10 mg (Memantine Hydrochloride)

Pelore 10 mg (Memantine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Memantine Hydrochloride›10mg / 1 tablet
Manufacturer / importer
Myongin Pharmaceutical Co., Ltd.
Appearance
Light yellow oval film-coated tablet
Packaging
30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 200501165 · Notified 2005.03.28 · Insurance code 651902310

Summary

Main use
Treatment of moderate to severe Alzheimer's disease
Who takes it
Adults
Adult dose
Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia, and only if a caregiver can periodically confirm that the patient is taking the medicine. Diagnosis should be made according to currently accepted guidelines. The clinical benefits of this medicine and the patient's tolerability of treatment should be reassessed periodically. This medicine is administered orally once daily, at the same time each day. If necessary, it may be administered twice daily. This medicine may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows, until the maintenance dose is reached. Week 1 (Days 1–7) Administer 5mg per day for 7 days. Week 2 (Days 8–14) Administer 10mg per day for 7 days. Week 3 (Days 15–21) Administer 15mg per day for 7 days. From Week 4 onward Administer 20mg per day. Maintenance dose: The recommended maintenance dose is 20mg per day. 2. Elderly patients: Based on clinical data, the recommended dose for elderly patients aged 65 years or older is 20mg per day. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated, the dose may be increased to 20mg per day according to the standard dose-escalation method after at least 7 days of treatment. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment: No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). As there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.

Ingredients

Manufacturer
Myongin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of moderate to severe Alzheimer's disease

  • Alzheimer's disease
View approved original text

This medication is used for the treatment of moderate to severe Alzheimer's disease.

How to take

Adult dose

Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia, and only if a caregiver can periodically confirm that the patient is taking the medicine. Diagnosis should be made according to currently accepted guidelines. The clinical benefits of this medicine and the patient's tolerability of treatment should be reassessed periodically. This medicine is administered orally once daily, at the same time each day. If necessary, it may be administered twice daily. This medicine may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows, until the maintenance dose is reached. Week 1 (Days 1–7) Administer 5mg per day for 7 days. Week 2 (Days 8–14) Administer 10mg per day for 7 days. Week 3 (Days 15–21) Administer 15mg per day for 7 days. From Week 4 onward Administer 20mg per day. Maintenance dose: The recommended maintenance dose is 20mg per day. 2. Elderly patients: Based on clinical data, the recommended dose for elderly patients aged 65 years or older is 20mg per day. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated, the dose may be increased to 20mg per day according to the standard dose-escalation method after at least 7 days of treatment. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment: No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). As there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.

Precautions

This medication should not be used in patients with hypersensitivity to its ingredients, severe liver disease, or severe kidney disease. Additionally, it contains lactose, so patients with lactose intolerance or specific genetic metabolic disorders should not take it. Patients with epilepsy or a history of seizures, as well as those taking certain NMDA antagonists, may have an increased risk of side effects and should use it with caution. Patients with conditions that can increase urine pH or those with recent myocardial infarction, heart failure, or uncontrolled hypertension should also be careful. Dizziness, headaches, constipation, drowsiness, and hypertension are potential side effects; if symptoms are severe, consult a physician. This medication may interact with others, especially when taken with NMDA antagonists, antipsychotic medications, skeletal muscle relaxants, or anticoagulants. Pregnant or nursing women should avoid use due to uncertainty of safety or consult a healthcare professional before making a decision. Safety and efficacy in children and adolescents under 18 years of age have not been established. Overdose may lead to symptoms such as confusion, drowsiness, dizziness, hallucinations, and seizures; in such cases, seek medical attention immediately. This medication can affect the central nervous system, so caution is required when driving or operating machinery. Lastly, keep this medication out of reach of children and do not transfer it to other containers for safety.

Side effects

  • Dizziness
  • headache
  • constipation
  • drowsiness
  • hypertension
  • fungal infection
  • drug hypersensitivity reaction
  • confusion
  • hallucinations
  • psychotic reactions
Show 20 more
  • balance disorder
  • gait abnormalities
  • seizures
  • heart failure
  • venous thrombosis
  • thromboembolism
  • dyspnea
  • vomiting
  • pancreatitis
  • elevated liver function test levels
  • hepatitis
  • fatigue
  • nonspecific fatigue
  • weakness
  • diarrhea
  • anxiety
  • aggressiveness
  • stupor
  • unconsciousness
  • double vision

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent the ingress of air and moisture, and it is best kept at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Light yellow oval film-coated tablet

Package unit

30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.